Seminars in Hematology
Publisher: Elsevier · ISSN 0037-1963 · 37 articles
- Sickle Cell Disease: Expanding the Frontiers of Pathophysiology and Therapeutics
- Pain in SCD—Many mechanisms and mysteries
- The many facets of cardiopulmonary complications in sickle cell disease
- More disease-modifying therapies for sickle cell disease: Are small molecules and drug repurposing the way forward?
- Evolving insights into mitochondrial presence in RBC in sickle cell disease: Red blood cell and reticulocyte pathophysiology, therapeutic strategies, and future directions
- The paradox of HbSC disease—Not so benign after all
- Cellular pathogenesis of HbSC disease
- outside front cover, PMS 8883 metallic AND 4/C
- Myeloproliferative Neoplasms: Finding Our Footing in a Shifting Landscape
- Germline predisposition in myeloproliferative neoplasms
- The thrombopoietin receptor in myeloproliferative neoplasms: A unifying mechanism of disease pathogenesis and therapeutic targeting
- Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis
- Management of myeloproliferative neoplasms in pregnancy: Essential thrombocythemia, polycythemia vera, and primary myelofibrosis
- Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know
- Closing the disease modification gap: Emerging therapies in myelofibrosis beyond JAK inhibition
- Current landscape and future directions for treatment of accelerated-phase and blast-phase myeloproliferative neoplasms
- Blood or marrow transplantation and cellular therapies in myeloproliferative neoplasms: A comprehensive review
- Ten years of clinical genetic therapies for sickle cell disease: Current and future directions
- Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies
- Alloimmunization in sickle cell disease: Addressing an ongoing clinical challenge
- The current state of cerebral complications of sickle cell disease
- Making space for cures: Conditioning for autologous hematopoietic stem cell gene therapies
- Defects in ribosomes and translational control in lymphoid leukemia and lymphoma
- Autologous gene therapy versus allogeneic transplantation for sickle cell disease and transfusion-dependent β-thalassemia: Choosing between 2 definitive therapies
- Sickle cell disease-specific barriers to in vivo hematopoietic stem cell gene therapy
- From ribosomal stress to clonal adaptation: Del(5q) MDS as a paradigmatic acquired ribosomopathy
- Evolution of Gene Therapy in Hematology
- When protein targeting fails: SRP pathway and hematopoietic disorders
- A small modification makes a big difference: rRNA modifications in hematopoiesis and leukemia
- Gene therapy for hemoglobinopathies